Matt Larew
Stock Analyst at William Blair
(4.74)
# 667
Out of 4,690 analysts
220
Total ratings
63.9%
Success rate
21.9%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NEO NeoGenomics | Rated: Hold | n/a | $18.05 | - | 2 | Aug 27, 2026 | |
| GH Guardant Health | Maintained: Buy | n/a | $161.50 | - | 3 | Aug 25, 2026 | |
| QGEN Qiagen | Rated: Hold | n/a | $43.11 | - | 3 | Aug 24, 2026 | |
| SERA Sera Prognostics | Reiterated: Buy | n/a | $2.07 | - | 2 | Aug 20, 2026 | |
| MDXH MDxHealth | Reiterated: Hold | n/a | $0.7207 | - | 1 | Aug 14, 2026 | |
| TECH Bio-Techne | Reiterated: Hold | n/a | $72.35 | - | 9 | Aug 12, 2026 | |
| MASS 908 Devices | Maintained: Buy | n/a | $10.73 | - | 14 | Aug 11, 2026 | |
| NTRA Natera | Reiterated: Buy | n/a | $326.26 | - | 1 | Aug 7, 2026 | |
| TXG 10x Genomics | Maintained: Buy | n/a | $61.54 | - | 10 | Aug 7, 2026 | |
| MRVI Maravai LifeSciences Holdings | Reiterated: Hold | n/a | $7.68 | - | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $26.83 | - | 1 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.12 | - | 9 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $93.24 | - | 1 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $21.03 | - | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $414.69 | - | 6 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $49.79 | - | 2 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $141.38 | - | 11 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $132.99 | - | 13 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $43.34 | - | 1 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $64.04 | - | 2 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $25.19 | - | 1 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $23.90 | - | 13 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.58 | - | 9 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $176.27 | - | 11 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $622.18 | - | 11 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $337.47 | - | 12 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $216.07 | - | 9 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.22 | - | 10 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $6.96 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $291.50 | - | 1 | Oct 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $78.63 | n/a | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $15.47 | n/a | 1 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $10.86 | n/a | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $180.68 | n/a | 4 | Sep 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $335.11 | n/a | 1 | Dec 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $120.85 | n/a | 1 | Nov 21, 2017 |
NeoGenomics
Aug 27, 2026
Rated: Hold
Price Target: n/a
Current: $18.05
Upside: -
Guardant Health
Aug 25, 2026
Maintained: Buy
Price Target: n/a
Current: $161.50
Upside: -
Qiagen
Aug 24, 2026
Rated: Hold
Price Target: n/a
Current: $43.11
Upside: -
Sera Prognostics
Aug 20, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.07
Upside: -
MDxHealth
Aug 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.7207
Upside: -
Bio-Techne
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $72.35
Upside: -
908 Devices
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $10.73
Upside: -
Natera
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $326.26
Upside: -
10x Genomics
Aug 7, 2026
Maintained: Buy
Price Target: n/a
Current: $61.54
Upside: -
Maravai LifeSciences Holdings
Aug 7, 2026
Reiterated: Hold
Price Target: n/a
Current: $7.68
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $26.83
Upside: -
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $7.12
Upside: -
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $93.24
Upside: -
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $21.03
Upside: -
Aug 4, 2026
Maintained: Buy
Price Target: n/a
Current: $414.69
Upside: -
Aug 3, 2026
Rated: Hold
Price Target: n/a
Current: $49.79
Upside: -
Aug 3, 2026
Reiterated: Buy
Price Target: n/a
Current: $141.38
Upside: -
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $132.99
Upside: -
Jul 31, 2026
Maintained: Buy
Price Target: n/a
Current: $43.34
Upside: -
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $64.04
Upside: -
Jul 30, 2026
Maintained: Buy
Price Target: n/a
Current: $25.19
Upside: -
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $23.90
Upside: -
Jul 29, 2026
Rated: Hold
Price Target: n/a
Current: $14.58
Upside: -
Jul 28, 2026
Maintained: Buy
Price Target: n/a
Current: $176.27
Upside: -
Jul 24, 2026
Maintained: Buy
Price Target: n/a
Current: $622.18
Upside: -
Jul 23, 2026
Maintained: Buy
Price Target: n/a
Current: $337.47
Upside: -
Jul 22, 2026
Maintained: Buy
Price Target: n/a
Current: $216.07
Upside: -
Jul 2, 2026
Rated: Hold
Price Target: n/a
Current: $1.22
Upside: -
May 11, 2026
Reiterated: Sell
Price Target: n/a
Current: $6.96
Upside: -
Oct 11, 2025
Upgraded: Buy
Price Target: n/a
Current: $291.50
Upside: -
Oct 8, 2024
Reiterated: Hold
Price Target: n/a
Current: $78.63
Upside: n/a
Aug 22, 2022
Maintained: Buy
Price Target: n/a
Current: $15.47
Upside: n/a
Sep 22, 2021
Downgraded: Hold
Price Target: n/a
Current: $10.86
Upside: n/a
Sep 11, 2019
Downgraded: Hold
Price Target: n/a
Current: $180.68
Upside: n/a
Dec 3, 2018
Maintained: Buy
Price Target: n/a
Current: $335.11
Upside: n/a
Nov 21, 2017
Initiated Coverage: Buy
Price Target: n/a
Current: $120.85
Upside: n/a